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a  b  s  t  r  a  c  t
Cytosine  arabinoside  (Ara-C)  is one  of  the  critical  agents  for  the  treatment  of  acute  myeloid  leukemia
(AML).  The  toxicity  proﬁle  of  Ara-C  is  highly  dependent  on the dose  and  schedule  of  administration.
Cardiologic  complications  associated  with  Ara-C  are  rare.  These  side  effects  were  reported  with  high
doses  of  cytarabine  (1–3 g/m2, 6–12  doses)  in  the literature.  Herein,  we  report  a patient  who  developed
symptomatic  sinus  bradycardia  while  receiving  low-dose  Ara-C  therapy  for  AML.  A  45-year-old  female
patient  diagnosed  with  AML  was treated  with  standard  remission  induction  chemotherapy  protocol
that  includes  3  days  of anthracycline  and 7 days  of low-dose  (100–200  mg/m2 2–1)  Ara-C.  The  same
chemotherapy  regimen  was  applied  again  on the 15th  day  of  admission.  During  the second  chemotherapy
cycle,  the  patient  developed  symptomatic  sinus  bradycardia.  All  causes  except  Ara-C  were  excluded  after
required  investigational  procedures.  Ara-C  infusion  was  discontinued  for a while  and  after  her  symptoms
passed  chemotherapy  was  completed  with  atropine  support.  Cardiac  toxicity  is  scarce  with  Ara-C.  We
want  to remind  that  clinicians  should  be aware  of  this  potential  toxic  manifestation  even  in low  doses  of
the  medication,  especially  as  Ara-C  is  widely  used  in  the  treatment  of  leukemia.
<Learning objective:  Cytosine  arabinoside  is one  of the  historic  chemotherapeutics  in hematology.  It  was
widely  used  to treat  many  types  of hematological  malignancies  in  high  doses  and  is  commonly  available
in  worldwide  markets.  Symptomatic  sinus  bradycardia  is  a  rare type of  cardiologic  side effect,  but  it
should  be kept  in  mind  during  chemotherapy.>
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Cytosine arabinoside (Ara-C) is a nucleoside analog in the group
f antimetabolite drugs. It represents a mainstay in the induction
reatment of acute myeloid leukemia (AML). It is also incorporated
nto some induction regimens for acute lymphoid leukemia (ALL).
enerally, it is used in combination with anthracyclines (7 days of
ra-C 100–200 mg/m2 and 3 days of daunorubicin). The major side
ffects of Ara-C are myelosupression and gastrointestinal toxicity
1].
Cardiopulmonary complications associated with Ara-C are rare.
hese side effects are supraventricular and ventricular arrhythmias,
ericarditis, acute respiratory distress syndrome, and congestive
eart failure. They are usually associated with high doses of cytara-
ine (1–3 g/m2, 6–12 doses) [2]. Herein, we report a patient who
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developed symptomatic sinus bradycardia while receiving low-
dose Ara-C as induction therapy (7 + 3) for AML.
Case report
A  45-year-old female patient presented with symptoms of
fatigue, high fever, and anorexia. Her skin and conjunctivae were
pale on physical examination. A normal cardiac examination with
an apex beat of 88/min, blood pressure of 110/70 mmHg, and fever
of 38 ◦C was  observed. Normal sinus rhythm was seen on elec-
trocardiography monitoring (ECG) (Fig. 1) and a normal echocar-
diography evaluation was observed with an ejection fraction of
69%. The laboratory values at presentation were; white blood cell
count, 87,000/mm3; hemoglobin, 8.6 g/dl; hematocrit, 26%; platelet
count, 14,000/mm3; lactate dehydrogenase, 455 myeloblasts were
created ninety percent of leucocytes (Auer body positive) were
shown on peripheral blood smear (Fig. 2), U/ml. Other labo-
ratory analyses were all in the normal range. Flow cytometric
analysis, which was performed in bone marrow, was compatible
with AML-M2 (CD 33, 89%, CD 13, 82%, and MPO, 74% posi-
tive). There was  a normal karyotype analysis and no cytogenetic
vier Ltd. All rights reserved.
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bFig. 1. Initial normal sinus rhy
nomalies were found. The patient was diagnosed with AML.
tandard remission induction therapy was initiated (7 + 3;
00 mg/m2/day of Ara-C for 7 days and 25 mg/m2/day doxorubicin
or 3 days). Granisetron was only used as an antiemetic before
reatment. The same course of chemotherapy regimen (7 + 3) was
pplied again because of the presence of 18% myeloblasts on bone
arrow aspiration that was performed on the 15th day of therapy.
 radial pulse of 42/min and arterial blood pressure of 80/60 mmHg
ere recorded on the fourth day of therapy. Hence, ECG monitor-
ng was performed, which showed sinus bradycardia (heart rate:
2/min). The corrected QT interval was calculated as 0.44 on the
CG showing bradycardia (Fig. 3). Normal levels of serum potas-
ium 4.1 mmol/l (3.5–5.5 mmol/l), calcium 9.1 mg/dl (9–11 mg/dl),
nd magnesium, and thyroid hormones were found. All other situ-
tions that can cause bradycardia were investigated. The standard
ose of Ara-C in the chemotherapy protocol was discontinued in
rder to treat the bradycardia. Pulse monitoring of the patient was
one carefully. The patient’s heart rate progressively elevated to
5/min after 3 days as a result of suspension of the therapy. Ther-
py was restarted with close rhythm monitoring and the support
ig. 2. Peripheral smear of the patient. Myeloblast was seen which contains Auer
ody in it (hematoxylin and eosin dye, with 100× magniﬁcation ﬁeld).f the patient at presentation.
of atropine. After the therapy had been restarted, despite the sup-
port of atropine, the pulse varied between 42 and 50/min. Two days
after the therapy ﬁnished, the patient’s heart rate was in the nor-
mal range and thereafter the pulse was  stabilized above 60/min
(Fig. 3).
As  a consolidation therapy, high dose Ara-C (HIDAC) (3.5 g/m2
totally 6 dose in every 12 h of day, on 1st, 3rd, and 5th days) was
administered as three cycles. The patient’s pulse was  in the nor-
mal range during these therapies. Before the fourth consolidation
therapy, a relapse was noticed and the patient died due to relapsed-
refractory AML.
Discussion
Ara-C  is an important antimetabolite agent that is used to
treat AML  [3]. The concentration of the drug and time of expo-
sure are principal markers of Ara-C toxicity, and the extracellular
drug concentration must be maintained between 10 and 15 mol/l
to provide optimum Ara-C cellular pharmacokinetics [4]. Toxicity
due to high doses of Ara-C includes myelosupression, gastroin-
testinal, pulmonary toxicity, and signiﬁcant but rarely irreversible
cerebellar toxicity [1]. Chemotherapeutic agents have some side
effects such as hypertension, cardiomyopathy, and long QT on ECG.
Agents such as cyclophosphamide (complete heart block), cisplatin
(left bundle branch block), paclitaxel (mobitz type 1 and 2 block
and complete heart block), and 5-ﬂuorouracil are associated with
bradycardia [5].
Congestive  heart failure may  occur in 20% of patients treated
with anthracycline, but so far the literature about sinus arrhythmia
is scarce and restricted to taxanes, high dose ifosfamide, and Ara-C,
mostly as anecdotal reports [6]. Fifteen cases of patients who
developed arrhythmias due to Ara-C are presented in the litera-
ture. Of these 15 cases, 1 had wide complex bradycardia, 1 had an
idioventricular rhythm, 10 out of the 15 had sinusal bradycardia, 1
had atrioventricular block, and 2 cases had uncharacterized brady-
cardia. All of these cases were treated with either intermediate- or
high-dose Ara-C (1–3 g/m2 bid on days 1, 3, and 5) [3,5–8]. Our case
differs from the reported ones in the literature because the patient
developed symptomatic sinus bradycardia with low-dose Ara-C.
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[Fig. 3. Sinus bradycardia with 42 beats/mi
The 7 + 3 protocol was applied as remission induction ther-
py, because the diagnosis was AML. There was  no bradycardia
bserved in this patient during the ﬁrst remission induction ther-
py. The second remission induction therapy (7 + 3) was applied
n order to get remission. The pulse was 42/min on the fourth
ay of treatment and the heart rate was conﬁrmed as 42/min on
CG. After interruption of the therapy, the heart rate progressively
eturned to normal. So the, treatment was resumed from the point
f interruption. After the ﬁrst Ara-C infusion, the patient devel-
ped symptomatic bradycardia again. It was concluded that the
radycardia was associated with the Ara-C treatment because other
robable causes of bradycardia (electrolyte imbalance, ischemic
ardiopathy, hypothermia, hypothyroidsm, typhoid fever, identiﬁ-
ble virus infection, cardioactive drug, morphine, etc.) had already
een excluded. The calculated Noranjo adverse drug reaction prob-
bility scale of the patient’s score was 10 and was  regarded as
eﬁnite according to this scale [9]. Therefore, it is reasonable to
peculate about a possible relationship between low-dose Ara-C
nd symptomatic sinus bradycardia observed in our patient.
The  real mechanism of bradycardia and cardiac effects due
o Ara-C are not known. It is suspected that they are associated
ith an immune-mediated process or a type of hypersensitivity
eaction [2]. All the reactions that cannot be explained by the mech-
nism of the drug are deﬁned as allergic reactions. Desensitization
immunotherapy) therapy aims to alter the immune response to
he drug and results in tolerance to the speciﬁc drug and allowing
he patient to receive a subsequent course of the medication safely.
radycardia that was reported in case reports in the literature often
eveloped during high-dose Ara-C therapy; however, in our case
t developed with low-dose Ara-C therapy. The hypersensitivity
eaction theory is supported because of the development of brady-
ardia during the second remission induction therapy while it did
ot develop during the ﬁrst remission induction therapy and high-
ose Ara-C. We  attribute the improvement of bradycardia during
igh-dose Ara-C to the desensitization to the Ara-C.
[ng low-dose cytosine arabinoside therapy.
In conclusion, neither this case nor the others cited above
provide conclusive evidence for a direct relationship between
bradycardia and Ara-C. Physicians need to take into account the
underlying disease and the concomitant medications. We  believe
that clinicians should be aware of this potential toxic manifestation
even in low doses of the medication, especially as Ara-C is widely
used in the treatment of leukemia.
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